Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (18)

2015

  1. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

2014

  1. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system

    Cellular and Molecular Life Sciences, Vol. 71, Núm. 23, pp. 4637-4651

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. Usage of Adenovirus Expressing Thymidine Kinase Mediated Hepatocellular Damage for Enabling Mouse Liver Repopulation with Allogenic or Xenogenic Hepatocytes

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

2011

  1. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells

    European Journal of Immunology, Vol. 40, Núm. 12, pp. 3389-3402

2009

  1. Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells

    Journal of Virology, Vol. 83, Núm. 7, pp. 3298-3311

2008

  1. Implication of human N-α-acetyltransferase 5 in cellular proliferation and carcinogenesis

    Oncogene, Vol. 27, Núm. 58, pp. 7296-7306

2006

  1. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: In vivo and in vitro studies

    Gut, Vol. 55, Núm. 8, pp. 1188-1196

  2. Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

    Molecular Therapy, Vol. 14, Núm. 1, pp. 129-138

2002

  1. The woodchuck interferon-α system: Cloning, family description, and biologic activity

    Journal of Medical Virology, Vol. 68, Núm. 3, pp. 424-432

2001

  1. Expression of interferon-α subtypes in peripheral mononuclear cells from patients with chronic hepatitis C: A role for interferon-α5

    Journal of Viral Hepatitis, Vol. 8, Núm. 2, pp. 103-110

1999

  1. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls

    Hepatology, Vol. 29, Núm. 6, pp. 1900-1904

1998

  1. Superoxide dismutase in patients with chronic hepatitis C virus infection

    Free Radical Biology and Medicine, Vol. 24, Núm. 7-8, pp. 1235-1241

1996

  1. Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

    Hepatology, Vol. 23, Núm. 2, pp. 210-217

1994

  1. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

    Journal of Hepatology, Vol. 21, Núm. 1, pp. 4-11

1992

  1. Tratamiento de la hepatitis crónica B con interferón alfa linfoblastoide: efectos en la inmunidad celular

    Gastroenterologia y Hepatologia, Vol. 15, Núm. 8, pp. 437-442